Last reviewed · How we verify

NCT05275803

Lactobacillus Reuteri for Non-surgical Periodontal Treatment of Chronic Periodontitis With Type 2 Diabetes Patients

Status unknown NA Last updated 7 June 2023
What this trial tests

NA trial testing Probiotics in Periodontitis in 48 participants. Status unknown.

Timeline
8 June 2023
Primary endpoint
20 June 2023
20 May 2024

Quick facts

Lead sponsorThe Dental Hospital of Zhejiang University School of Medicine
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment48
Start date8 June 2023
Primary completion20 June 2023
Estimated completion20 May 2024

Drugs / interventions tested

Conditions studied

Sponsor

The Dental Hospital of Zhejiang University School of Medicine

Who can join

Adults 35 to 70, any sex, with Periodontitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the clinical and microbiological efficacy of Lactobacillus reuteri as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis with type 2 diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Recent advances in therapeutic probiotics: insights from human trials.
    Cho M-Y, Eom J-H, Choi E-M, Yang S-J, et al · · 2025 · cited 17× · PMID 40261032 · DOI 10.1128/cmr.00240-24

Verify or expand the search:

Other trials of Probiotics

Trials testing the same drug.

Other recruiting trials for Periodontitis

Currently open trials in the same condition.

Other The Dental Hospital of Zhejiang University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05275803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing